Viewing Study NCT04792502


Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-03-03 @ 3:55 AM
Study NCT ID: NCT04792502
Status: RECRUITING
Last Update Posted: 2025-03-21
First Post: 2021-03-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Sponsor: Brown University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Follicular Lymphoma View
None Marginal Zone Lymphoma View
None B-cell Lymphoma View
Keywords: